Zepbound vs Mounjaro: Understanding Tirzepatide for Weight Loss and Diabetes

Zepbound vs Mounjaro: Understanding the Differences Between Tirzepatide for Weight Loss and Diabetes

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Tirzepatide: A Dual-Action Breakthrough

Tirzepatide is the first-in-class dual GIP/GLP-1 receptor agonist. Unlike semaglutide (which targets only GLP-1 receptors), tirzepatide simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual mechanism produces several advantages:

• Greater weight loss: Head-to-head in the SURMOUNT-5 trial, tirzepatide 15mg produced 20.2% weight loss vs. 13.7% for semaglutide 2.4mg — a 47% improvement.
• Superior glucose control: A1c reduction of 2.0-2.3% with tirzepatide vs. 1.5-1.8% with semaglutide in diabetes trials.
• Better insulin sensitivity: GIP receptor activation independently improves insulin secretion and beta-cell function.
• Potential for better tolerability: Some data suggest GIP activation partially mitigates the nausea caused by GLP-1 activation, though GI side effects remain common.

Mounjaro vs. Zepbound: The Differences

FDA-Approved Indications

Mounjaro: Type 2 diabetes mellitus, as an adjunct to diet and exercise. Approved November 2022.

Zepbound: Chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Approved November 2023.

Dosing (Identical)

Both follow the same titration: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, with each step lasting a minimum of 4 weeks. The injection device (KwikPen) is the same. The only difference is the box label.

Clinical Trial Programs

Mounjaro (SURPASS trials):

• SURPASS-1: Tirzepatide monotherapy. A1c reduction: 1.87-2.07%. Weight loss: 15-20 lbs.
• SURPASS-2: vs. semaglutide 1mg. Tirzepatide was superior for A1c reduction at all doses.
• SURPASS-3: vs. insulin degludec. Tirzepatide produced A1c reduction + weight loss, while insulin caused weight gain.

Zepbound (SURMOUNT trials):

• SURMOUNT-1: 22.5% weight loss at 15mg dose (72 weeks). 1 in 3 patients lost >25% of body weight.
• SURMOUNT-2: In patients with type 2 diabetes + obesity: 14.7% weight loss (diabetes blunts the weight loss effect).
• SURMOUNT-3: After initial lifestyle-only weight loss, adding tirzepatide produced an additional 18.4% weight loss.
• SURMOUNT-4: Continuing tirzepatide maintained weight loss; switching to placebo resulted in regain of 14% over 36 weeks.
• SURMOUNT-5: Head-to-head vs. semaglutide 2.4mg. Tirzepatide won: 20.2% vs. 13.7%.

Insurance and Access

Mounjaro: Covered by most insurance plans for type 2 diabetes with prior authorization. Copay assistance programs available for commercially insured patients.

Zepbound: Coverage is inconsistent. Many plans exclude weight management medications. Medicare does not currently cover Zepbound for weight loss. Out-of-pocket cost: approximately $1,060/month. Eli Lilly offers a savings card program for eligible patients.

Managing Side Effects on Tirzepatide

The side effect profile is similar between Mounjaro and Zepbound (same drug, same effects):

GI Side Effects (Most Common)

• Nausea: 12-33% depending on dose. Usually worst during weeks 1-4 of each dose increase.
• Diarrhea: 12-21%. Can alternate with constipation.
• Constipation: 6-11%. Managed with magnesium, hydration, and fiber.
• Decreased appetite: This is the desired effect but can lead to insufficient nutrition if not managed proactively.

Management Strategies

• Eat smaller, more frequent meals
• Prioritize protein at every eating occasion (1.2-1.6g/kg body weight daily)
• Use Casa de Sante Whey Protein for easy protein intake when appetite is low
• Take Casa de Sante Digestive Enzymes with meals to support the slower digestive process
• Hydrate proactively — 64-80oz daily
• Ginger (tea or capsules) for nausea management
• Avoid lying down within 2 hours of eating

Which Should You Take?

The choice between Mounjaro and Zepbound is typically determined by your diagnosis and insurance rather than clinical preference:

• If you have type 2 diabetes: Mounjaro (better insurance coverage)
• If you have obesity without diabetes: Zepbound (correct FDA indication)
• If you have both: either may be appropriate — discuss with your prescriber which indication to use for insurance purposes

Frequently Asked Questions

Is tirzepatide better than semaglutide?

For weight loss, the head-to-head data from SURMOUNT-5 shows tirzepatide produces significantly more weight loss than semaglutide (20.2% vs. 13.7%). For diabetes, tirzepatide also produced better A1c reduction in SURPASS-2. However, individual responses vary, and some patients respond better to one medication than the other. Cost and insurance coverage are often the deciding practical factors.

Can my doctor prescribe Mounjaro for weight loss?

Off-label prescribing is legal. Many physicians prescribed Mounjaro for weight loss before Zepbound was approved. Insurance may not cover this off-label use, but the medication itself is identical whether prescribed as Mounjaro or Zepbound.

What happens when I reach the maximum dose?

Not everyone needs the 15mg dose. Many patients achieve their goals at 5mg, 7.5mg, or 10mg. Your prescriber will help determine the dose that balances efficacy with tolerability. Staying at a lower tolerable dose is preferred over pushing to maximum dose with significant side effects.

Can I switch from Ozempic/Wegovy to Mounjaro/Zepbound?

Yes, under physician guidance. Since they are different drug classes, there is no direct dose equivalence. Most prescribers start tirzepatide at 2.5mg regardless of prior semaglutide dose, then titrate upward based on response. Switching is most common when patients plateau on semaglutide or want greater weight loss.